Page 83 - Read Online

Page 16 of 18 Malentacchi et al. J Cancer Metastasis Treat 2020;6:34 I http://dx.doi.org/10.20517/2394-4722.2020.34

38. Malentacchi F, Pizzamiglio S, Verderio P, Pazzagli M, Orlando C, et al. Influence of pre-analytical phase on circulating cell free DNA
(ccfDNA): the SPIDIA-DNAplas external quality assessment experience. Clin Chem Lab Med 2015;53:1935-42.
39. Nakauchi C, Kagara N, Shimazu K, Shimomura A, Naoi Y, et al. Detection of TP53/PIK3CA mutations in cell-free plasma DNA from
metastatic breast cancer patients using next generation sequencing. Clin Breast Cancer 2016;16:418-23.
40. Zeng C, Stroup EK, Zhang Z, Chiu BCH, Zhang W. Towards precision medicine: advances in 5-hydroxymethylcytosine cancer biomarker
discovery in liquid biopsy. Cancer Commun 2019;39:12.
41. Kerachian MA, Poudineh A, Thiery JP. Cell free circulating tumor nucleic acids, a revolution in personalized cancer medicine. Crit Rev
Oncol Hematol 2019;144:102827.
42. Li L, Zhang J, Jiang X, Li Q. Promising clinical application of ctDNA in evaluating immunotherapy efficacy. Am J Cancer Res
2018;8:1947-56.
43. Vidal J, Taus A, Montagut C. Dynamic treatment stratification using ctDNA. Recent Results Cancer Res 2020;215:263-73.
44 Zhu Y, Yang T, Wu Q, Yang X, Hao J, et al. Diagnostic performance of various liquid biopsy methods in detecting colorectal cancer: a
meta-analysis. Cancer Med 2020;9:5699-707.
45. Koessler T, Paradiso V, Piscuoglio S, Nienhold R, Ho L, et al. Reliability of liquid biopsy analysis: an inter-laboratory comparison of
circulating tumor DNA extraction and sequencing with different platforms. Lab Invest 2020; doi: 10.1038/s41374-020-0459-7.
46. Moon SM, Kim JH, Kim SK, Kim S, Kwon HJ, et al. Clinical utility of combined circulating tumor cell and circulating tumor DNA
assays for diagnosis of primary lung cancer. Anticancer Res 2020;40:3435-44.
47. Kerachian MA, Azghandi M, Javadmanesh A, Ghaffarzadegan K, Mozaffari-Jovin S. Selective capture of plasma cell-free tumor DNA on
magnetic beads: a sensitive and versatile tool for liquid biopsy. Cell Oncol (Dordr) 2020; doi: 10.1007/s13402-020-00536-2.
48. Pittella-Silva F, Chin YM, Chan HT, Nagayama S, Miyauchi E, et al. Plasma or serum: which is preferable for mutation detection in
liquid biopsy? Clin Chem 2020;66:946-57.
49. Sato Y, Matoba R, Kato K. Recent advances in liquid biopsy in precision oncology research. Biol Pharm Bull 2019;42:337-42.
50. Dobrzycka B, Terlikowski SJ, Mazurek A, Kowalczuk O, Niklinska W, et al. Circulating free DNA, p53 antibody and mutations of KRAS
gene in endometrial cancer. Int J Cancer 2010;127:612-21.
51. Bolivar AM, Luthra R, Mehrotra M, Chen W, Barkoh BA, et al. Targeted next-generation sequencing of endometrial cancer and matched
circulating tumor DNA: identification of plasma-based, tumor-associated mutations in early stage patients. Mod Pathol 2019;32:405-14.
52. Iwahashi N, Sakai K, Noguchi T, Yahata T, Matsukawa H, et al. Liquid biopsy-based comprehensive gene mutation profiling for
gynecological cancer using cancer personalized profiling by deep sequencing. Sci Rep 2019;9:10426.
53. Vizza E, Corrado G, De Angeli M, Carosi M, Mancini E, et al. Serum DNA integrity index as a potential molecular biomarker in
endometrial cancer. J ExpClin Cancer Res 2018;37:16.
54. Nakabayashi M, Kawashima A, Yasuhara R, Hayakawa Y, Miyamoto S, et al. Massively parallel sequencing of cell-free DNA in plasma
for detecting gynaecological tumour associated copy number alteration. Sci Rep 2018;8:11205.
55. Tanaka H, Tsuda H, Nishimura S, Nomura H, Kataoka F, et al. Role of circulating free alu DNA in endometrial cancer. Int J Gynecol
Cancer 2012;22:82-6.
56. Cicchillitti L, Corrado G, De Angeli M, Mancini E, Baiocco E, et al. Circulating cell-free DNA content as blood based biomarker in
endometrial cancer. Oncotarget 2017;8:115230-43.
57. An Q, Hu Y, Li Q, Chen X, Huang J, et al. The size of cell-free mitochondrial DNA in blood is inversely correlated with tumor burden in
cancer patients. PrecisClinMed 2019;2:131-9.
58. Pasha HA, Rezk NA, Riad MA. Circulating cell free nuclear DNA, mitochondrial DNA and global DNA methylation: potential
noninvasive biomarkers for breast cancer diagnosis. Cancer Invest 2019;37:432-9.
59. Meng X, Schwarzenbach H, Yang Y, Müller V, Li N, et al. Circulating mitochondrial DNA is linked to progression and prognosis of
epithelial ovarian cancer. TranslOncol 2019;12:1213-20.
60. Afrifa J, Zhao T, Yu J. Circulating mitochondria DNA, a non-invasive cancer diagnostic biomarker candidate. Mitochondrion
2019;47:238-43.
61. Mair R, Mouliere F, Smith CG, Chandrananda D, Gale D, et al. Measurement of plasma cell-free mitochondrial tumor DNA improves
detection of glioblastoma in patient-derived orthotopic xenograft models. Cancer Res 2019;79:220-30.
62. Weerts MJA, Timmermans EC, van de Stolpe A, Vossen RHAM, Anvar SY, et al. Tumor-specific mitochondrial DNA variants are rarely
detected in cell-freeDNA. Neoplasia 2018;20:687-96.
63. Tan ZQ, Liu FX, Tang HL, Su Q. Expression and its clinical significance of hsa-miR-155 in serum of endometrial cancer. Zhonghua Fu
Chan Ke Za Zhi 2010;45:772-4.
64. Zhai H, Karaayvaz M, Dong P, Sakuragi N, Ju J. Prognostic significance of miR-194 in endometrial cancer. Biomark Res 2013;1:12.
65. Torres A, Torres K, Pesci A, Ceccaroni M, Paszkowski T, et al. Deregulation of miR-100, miR-99a and miR-199b in tissues and plasma
coexists with increased expression of mTOR kinase in endometrioid endometrial carcinoma. BMC Cancer 2012;12:369.
66. Torres A, Torres K, Pesci A, Ceccaroni M, Paszkowski T. Diagnostic and prognostic significance of miRNA signatures in tissues and
plasma of endometrioid endometrial carcinoma patients. Int J Cancer 2013;132:1633-45.
67. Tsukamoto O, Miura K, Mishima H, Abe S, Kaneuchi M, et al. Identification of endometrioid endometrial carcinoma-associated
microRNAs in tissue and plasma. GynecolOncol 2014,132:715-21.
68. Wang WT, Zhao YN, Yan JX, Weng MY, Wang Y, et al. Differentially expressed microRNAs in the serum of cervical squamous cell
carcinoma patients before and after surgery. J Hematol Oncol 2014;7:6.
69. Yu J, Wang Y, Dong R, Huang X, Ding S, et al. Circulating microRNA-218 was reduced in cervical cancer and correlated with tumor